Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | CES1 | P23141 | 1/20 | 0.39 |
| ▸ | KCNN4 | O15554 | 4/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | CA4 | P22748 | 1/20 | 0.35 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | ESR1 | P03372 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2154443 | 0.75 | CES1 (0.47) | TSHRMAPK1CES1KCNN4ALDH1A1 | |
| SCHEMBL10707751 | 0.75 | TSHR (0.50) | TSHRMAPK1CES1KCNN4ALDH1A1 | |
| SCHEMBL4073627 | 0.75 | TSHR (0.50) | TSHRMAPK1CES1KCNN4ALDH1A1 | |
| SCHEMBL10499996 | 0.75 | TSHR (0.50) | TSHRMAPK1CES1KCNN4ALDH1A1 | |
| SCHEMBL29254252 | 0.75 | MAPK1 (0.44) | TSHRMAPK1CES1KCNN4ALDH1A1 | |
| SCHEMBL6299817 | 0.73 | MAPK1 (0.42) | TSHRMAPK1CES1KCNN4ALDH1A1 | |
| SCHEMBL9047900 | 0.73 | MAPK1 (0.48) | TSHRMAPK1CES1KCNN4ALDH1A1 | |
| SCHEMBL8471164 | 0.73 | CYP1A2 (0.45) | TSHRMAPK1CES1KCNN4ALDH1A1 | |
| SCHEMBL11034971 | 0.72 | MAPK1 (0.46) | TSHRMAPK1CES1KCNN4ALDH1A1 | |
| SCHEMBL11637695 | 0.72 | TSHR (0.52) | TSHRMAPK1KCNN4ALDH1A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2903990-B1 | THERAPEUTICALLY ACTIVE OXAZOLINE DERIVATIVES | UCB BIOPHARMA SPRL (BE) | 2017-06-14 | — | — | EP | disclosed |
| EP-2744812-B1 | THERAPEUTICALLY ACTIVE FUSED PYRIMIDINE DERIVATIVES | UCB BIOPHARMA SPRL (BE) | 2016-07-20 | — | — | EP | disclosed |
| US-9382263-B2 | Therapeutically active oxazoline derivatives | UCB BIOPHARMA SPRL (BE) | 2016-07-05 | — | — | US | disclosed |
| US-9227984-B2 | Therapeutically active fused pyrimidine derivatives | UCB PHARMA S.A. (BE) | 2016-01-05 | — | — | US | disclosed |
| US-20150274748-A1 | Therapeutically Active Oxazoline Derivatives | UCB BIOPHARMA SPRL (BE) | 2015-10-01 | — | — | US | disclosed |
| EP-2903990-A1 | THERAPEUTICALLY ACTIVE OXAZOLINE DERIVATIVES | UCB Biopharma SPRL (BE) | 2015-08-12 | — | — | EP | disclosed |
| US-20140309222-A1 | Therapeutically Active Fused Pyrimidine Derivatives | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U.LEUVEN R&D (BE) | 2014-10-16 | — | — | US | disclosed |
| EP-2744812-A2 | THERAPEUTICALLY ACTIVE FUSED PYRIMIDINE DERIVATIVES | UCB Pharma, S.A. (BE) | 2014-06-25 | — | — | EP | disclosed |
| WO-2014053581-A1 | THERAPEUTICALLY ACTIVE OXAZOLINE DERIVATIVES | UCB PHARMA S.A. (BE) | 2014-04-10 | — | — | WO | disclosed |
| WO-2013024291-A2 | THERAPEUTICALLY ACTIVE FUSED PYRIMIDINE DERIVATIVES | UCB PHARMA S.A. (BE) | 2013-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150274748-A1 | Therapeutically Active Oxazoline Derivatives | ICOS, HAVCR2, CD74 | TSHR 2959/4885MAPK1 1099/4885CES1 2275/4885 |
| US-20140309222-A1 | Therapeutically Active Fused Pyrimidine Derivatives | HAVCR2, TPMT, PAICS | TSHR 3199/4885MAPK1 2657/4885CES1 2632/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.